The University of Arizona/Arizona Cancer Center (ACC) has been a continuously funded member institution of the Southwest Oncology Group (SWOG) since 1974. The current renewal application requests funding for years 37-41 to continue and expand institutional participation in the clincal research and treatment goals of SWOG via SWOG-and SWOG-endorsed efforts.
Specific aims and objectives remain as follows: 1. To continue to meet institutional scientific leadership and core service commitments within the Group, including: (a) protocol coordination (multiple studies);(b) disease and discipline committee administration;(c) reference and repository laboratory administration (including lymphoma, myeloma);(d) Group quality assurance and quality control. 2. To continue to promote the rapid integration of promising new research leads, including those developed at the ACC, into cooperative group testing to provide treatment options for a larger population of patients and improved patient care. 3. To continue to meet institutional clinical research commitments in the recruitment of appropriate patients for SWOG and SWOG-endorsed studies and all attendant commitments to longterm fllowup, quality assurance, quality control. 4. To continue and increase effforts to promote physician and patient awareness of and participation in SWOG and SWOG-endorsed clinical trials and outreach programs. 5. To continue efforts to understand factors affecting accrual paticularly those in special populations (eg, minority, elderly, financially disadvantaged) and to implement appropriate interventions where possible.

Public Health Relevance

The ACC has a long history of scientific and administrative leadership in the SWOG and participation in national cooperative group treatment and prevention studies. A key element of its scientific contribution is institutional clinical and laboratory pilot work leading to national testing to establish new standards of care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arizona
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Kelly, Jennifer L; Salles, Gilles; Goldman, Bryan et al. (2015) Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol 33:1482-90
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7

Showing the most recent 10 out of 202 publications